Q4 FY25 Quarterly Investor Presentation & Webinar
Released
Released
Announcement PDF
ASX Announcement
22 July 2025
Q4 FY25 Quarterly Investor Presentation & Webinar
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide below its Q4 FY25 Investor
Presentation and Investor Webinar with CEO Dr Luke Reid presenting.
Quarterly Investor Webinar
Presented by: CEO, Dr Luke Reid
Date & Time: 12:00pm (midday) AEST on Wednesday, 23 July 2025
Webinar Registration: Registration is required to attend the Quarterly Investor Webinar. Please register for the Webinar via
Microba’s Investor Hub at the following link: https://ir.microba.com/webinars/4PKExe-q4-fy25-quarterly-investor-webinar
Submit Your Questions
We invite investors and interested parties to submit questions ahead of the Quarterly Investor Webinar through the ‘Ask a
question’ section of Microba’s interactive investor platform by following this link: https://ir.microba.com/webinars/4PKExeq4-fy25-quarterly-investor-webinar
Stay Informed
To receive notifications when Microba releases its Quarterly Reports & Appendix 4C, Investor Presentations, and other key
announcements, sign up to the Microba Investor Hub:
1.
Visit https://ir.microba.com/welcome
2.
Follow the prompts to sign up for an account.
3.
Complete your account profile.
This announcement has been authorised for release by the Board of Directors
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
For more Company information and to engage with management by asking questions about Microba’s latest
announcements and updates, visit ir.microba.com/welcome
Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
At the forefront of microbiome
diagnostics & therapeutics
Q4 FY25 Results
ASX: MAP
22 JULY 2025
Authorised for release by the Board of Directors
Disclaimer
This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba).
Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any
obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in
evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act).
Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including
industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.
Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is
not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you
should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.
Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been
prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this
Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment
objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.
Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial
or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and
other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect",
"intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking
statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of
Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results,
performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at
the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.
Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for
illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance.
Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in
this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.
Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or
damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency,
accuracy, reliability or completeness of this Presentation.
2
Key Risks & Forward Financial Information Assumptions
Forward Financial Information Assumptions
above), followed by further scale in existing markets.
The achievement of the FY26 forward information & ~3-year strategic objectives detailed in slide 4 is • Assumes that Operating Expenses, Product Development and Corporate Expenditure grow at a rate
below revenue growth, enabling operating leverage.
based on the below key assumptions, and deviation in the Company’s ability to achieve or not achieve
these key assumptions, may materially affect the Company’s ability to execute these objectives. Refer • Assumes that new geographies or product development programs do not materially increase
operating expenditure during the period.
to slide 2 for the general disclaimer relating to 'future performance'. The assumptions specific to the
FY26 forward information & ~3-year strategic objectives are set out below.
Strong YoY Core Test Growth – Australia & United Kingdom – Assumptions
• Growth targets assumed in the Group EBITDA Break-even plan assumes continued strong clinical
FY26 Outlook Assumptions
adoption by innovator and early adopter clinicians and broader market penetration.
• YoY core test volume growth of 100% assumes continued clinician adoption growth in Australia and
• Assumed strong YoY growth is dependent on the availability of sufficient capital to support planned
the UK market.
commercial expansion, product development and operational scaling. In the event that capital is not
- Increased clinician adoption, including continued growth of new clinician accounts and
secured at anticipated levels, these objectives may be delayed or may not be achieved.
maintenance of existing test referral rates in Australia & the United Kingdom
- New product feature releases.
Initial Market Penetration – United States & Europe – Assumptions
• Assumed core test pricing aligned with existing competitor predicate tests in market.
FY26 break-even milestones - Assumptions
• Based on operating break-even at a regional level (forecasted to be achieved at test volumes of • Entry into the US and Europe is expected to be limited to one initial geography in each region.
• Assumes Laboratory Developed Test (LDT) regulatory pathway remains accessible in the US, and
>24,000, split across Australia and the UK)
CLIA accreditation is achieved for Microba central laboratory in Australia to service the initial
• Break-even figures are on a regional EBITDA basis only and exclude Corporate, Product
development of the US market
Development Expenditure and Share Based Payments expense.
• Australia break-even and UK break-even figures are based on forecast test pricing, targeted gross • Assumes successful establishment of laboratory service partnership and logistics with The Doctors
Laboratory (a subsidiary of Sonic Healthcare) to service volume from the UK and Europe
margins, and assumed operating cost structures for each geography.
• Test pricing and gross margins are assumed to remain stable over FY25–FY26, with no material • Assumes supportive regulatory, geopolitical and tariff environment and no material delays in market
access.
changes.
• Operational costs assume continued efficiencies from fixed infrastructure and modest scaling of • Assumes no requirement for reimbursement, cash pay sales are considered only.
commercial and support functions, including advancement and implementation of product- • Modest investment has been included, no material CAPEX expenditure has been incorporated, with
existing and partner laboratories utilised to service growth in test volume.
assisted/led growth models.
• UK break-even assumptions are modelled using an AUD:GBP exchange rate of 0.48.
• Assumes no material disruption from regulatory changes, macroeconomic & geopolitical shifts, or Transformative Patient Outcomes – Assumptions
• Qualitative and based on the frequency of patient outcomes shown from existing study data on
competitive pricing actions.
Microba’s core tests, and the anticipated growth in patient test usage and resulting continued
• Forecasts are contingent on execution of FY26 revenue plan and sufficient capital allocation to
growth in clinician adoption
support commercial execution and product development.
~3 Year Strategic Objective Assumptions
Group EBITDA Break-even - Assumptions
• Group break-even assumes successful execution of the FY26 regional break-even milestones (see
3
“We are building the platform
for personalised, microbiomebased healthcare.”
4
~3 Year
Strategic Objective
FY26
FY25
Grow early clinical adoption.
UK market expansion.
161%
Expand clinical adoption.
Break-even in Australia &
United Kingdom1.
Break-even
Group EBITDA
>100%
YoY core test growth
YoY core test growth
$15.67m
Regional Break-even
Revenue
In Australia & United Kingdom1
12,631
>24,000
Core test volume
Strong penetration of
innovator & early adopter
clinicians. Transformative
patient outcomes across
core regions.
Core test volume
Australia
Strong YoY growth
United Kingdom
Strong YoY growth
United States
Momentum in first state
Europe
Momentum in first country
The information on this slide includes forward financial information (Forward Financial Information). The Forward Financial Information has been prepared by Microba Life Sciences Ltd based on management best estimate assumptions which relate to future event(s) that Microba expects to occur and actions
that Microba expects to take and are also subject to uncertainties and contingencies, which are often outside the control of Microba. While all reasonable endeavours have been made to ensure both the robustness of the assumptions on which the Forward Financial Information is based and that such
assumptions are true, complete and accurate, such assumptions are generally future-oriented and therefore speculative in nature. 'Refer to slide 2 Financial Information Assumptions') for detail on both the assumptions and risks underpinning the FY26 numbers and ~3 Year Strategic Objective.
5
SECTION 1
Q4 FY25 Results
Financial Highlights
Q4 Financial Highlights
6
Continued Growth & Clinical Adoption of Testing Products in Australia and the UK
3,451 AU MetaXplore tests sold (+88% vs PCP) | 429 UK MetaXplore tests sold (+74% QoQ, PCP not applicable) | 266 AU MetaPanel tests sold (+85% vs PCP)
Continued Growth in Test Volumes
4,500
Australia
+88%
4,000
3,500
•
Continued strong sales momentum for MetaXplore with Q4 annualised
run rate of 13,800 MetaXplore tests sold, up 88% vs PCP.
•
Growth underpinned by a continued increase in the number of ordering
clinicians
•
Landmark GI Study Results from over 4,600 patients with 71.4%
identifying actionable results
3,000
2,500
2,000
1,500
United Kingdom
1,000
•
Full market access was achieved at the end of May 25, with June 25
delivering a record month
•
Strong growth, up 74% QoQ, underpinned by strong clinician adoption
•
MetaXplore tests now represent 66% of GI tests sold in the UK business
500
0
Q4FY24
Q1FY25
MetaXplore (AUS)
Q2FY25
Q3FY25
MetaPanel (AUS)
Q4FY25
MetaXplore (UK)
Q4 Financial Highlights
7
Strong close to FY25, despite impact from strategic change in revenue mix
FY25 revenue of $15.67m, up 30% vs PCP, and in line with previous guidance to the market
Quarterly Revenue
Annual Revenue Growth
$18,000,000
$16,000,000
$14,000,000
$12,000,000
$10,000,000
+30%
$6,000,000
•
Q4 revenue up 23% QoQ, and
down 13.5% vs PCP due to
discontinued legacy products
and services revenue (legacy rev.
included in light & dark green)
•
Underlying Personal Testing &
Supplements business (dark
green) up 23% QoQ, and 3.7% vs
PCP despite transitionary phase
•
Record Quarter for all core
products (MetaXplore and
MetaPanel) and regions Australia
and United Kingdom
Strategic product &
revenue transition period
$5,000,000
$4,000,000
$3,000,000
$8,000,000
$6,000,000
$4,000,000
$2,000,000
$2,000,000
$1,000,000
Personal Testing
& Supplements
+3.7%
$0
$0
Personal Testing & Supplements
Research Services
Strong clinical adoption & accelerating growth
Growth
Core tests & clinical software
winning a major new $25B
diagnostic category
8
$2,000,000
$1,500,000
$1,000,000
$500,000
$0
Base
To continue with opportunity
for future growth.
Q3FY24
Q4FY24
Q1FY25
Q2FY25
Q3FY25
Q4FY25
Q3FY24
Q4FY24
Q1FY25
Q2FY25
Q3FY25
Q4FY25
Q3FY24
Q4FY24
Q1FY25
Q2FY25
Q3FY25
Q4FY25
$2,000,000
$1,000,000
(Supplements, Strategic International Partners)
$0
Legacy
Products & services being discontinued &
phased out.
$2,000,000
$1,000,000
(Research services, UK EcologiX test, AU Insight test)
$0
Chart x-axis are sales $ AUD
9
SECTION 2
Q4 FY25 Results
Business Highlights
10
SUB-SECTION 2.1
KEY HIGHLIGHTS
Key Results
11
DIAGNOSTICS
THERAPEUTICS
1) Australia: Continued strong sales momentum for MetaXplore
All research and
development investment
stopped.
-
3,451 tests sold, up 88% vs PCP, a record quarter
790 ordering clinicians, up 89% vs PCP
Landmark GI Study Results from over 4,600 patients with 71.4% identifying
actionable results
2) Australia: MetaPanel adoption continues to build
-
266 tests sold, up 85% vs PCP
Study delivers breakthrough results revealing pathogens in 20% of patients
3) United Kingdom: Continued growth in MetaXplore test sales
-
429 tests sold, up 74% on QoQ
Full market access was achieved at the end of May, with June delivering a record
month
MetaXplore tests represent 66% of GI tests sold in the UK business as of 30 June
All therapeutic core asset
intellectual property
maintained, and focus is
now exclusively on
partnering.
2 upcoming sector deal
catalysts, expected in late
CY2025.
Major Clinical Study Results
12
Released to ASX 14 May 2025
Released to ASX 21 May 2025
Inflammatory Bowel Disease (IBD)
Chronic GI Symptoms
GI Infectious Disease
• MetaPanel test identifies gastrointestinal
pathogens in >35% of IBD patients experiencing
flare
• 71.4% of reports from 4,616 patients identified
actionable results
• Analysis of 889 MetaPanel tests shows that:
Released to ASX 30 April 2025
• >60% of these pathogens are missed by current
routine testing methods
Study 1
• These findings have the potential to shift
treatment protocols and provide a new path to
remission for IBD patients, avoiding unnecessary
therapy escalation or surgery
Flare
Study 2
Remission
Severe
flare
• A separate study of 84 patients by Microba who
received MetaXplore-guided care found that
65.5% reported health improvements after
following their clinician’s recommendations
• These results highlight the clinical value of
MetaXplore test results in advancing outcomes for
patients with chronic lower gastrointestinal
disorders, highlighting the potential to reshape
clinical management of these conditions and set a
new standard of care
71.4%
Positive
Positive MetaPanel
“These results are compelling, both as a clinical
use case for MetaPanel, and for the future of
precision medicine in gastroenterology. For
clinicians like myself managing complex IBD
cases, the ability to detect pathogens missed by
routine testing could transform how patients
are treated.”
Associate Professor Graham Radford-Smith
28.7%
Negati…
19.6%
Multiple
Markers
41.9%
Microbiome
Marker
9.9% Gastrointestinal
Marker
“MetaXplore enables me to objectively identify microbiome
dysbiosis, evaluate dietary quality, and direct patients toward
evidence-based nutritional strategies. Importantly, it helps
differentiate patients with normal GI and microbial profiles who
may benefit from psychological support rather than further invasive
testing or pharmacological escalation.”
• 20.0% of patients test positive for a pathogen
that can cause gastrointestinal infection
• 78.4% of the pathogens detected by
MetaPanel are often missed by routine
pathology tests
• Additionally, 58.3% of tests reveal abnormal
microbiome results
• 100% of patients treated for a pathogen detected
by MetaPanel experienced complete symptom
resolution in an independent study.
New Product Feature Releases
Marker Cards
Released into MetaXplore July 2025
The MetaXplore report has been updated for
improved clarity, with a more intuitive visual
summary of key results through Marker Cards.
Marker data is now shown as Marker Cards,
replacing distance from average and relative
abundance with a direct comparison to the
Microba healthy cohort data.
Each card represents a Pathogen, GI, or
Microbiome marker, designed for faster, clearer
result interpretation.
13
New Product Feature Releases
Report Share Version 2
Released into MetaXplore June 2025
The new Report Sharing feature gives patients
secure control over who can access their
MetaXplore reports, while also enabling
practitioners to share results directly with peers
via the Practitioner Portal.
This strengthens patient trust, streamlines
clinician workflows, and supports more
collaborative care.
It also sets the foundation for future features
and unlocks new levers for referral growth,
practitioner activation, and clinical
engagement.
14
15
SUB-SECTION 2.2
GROWTH
Core diagnostic tests & clinical software winning a
major new $25B diagnostic category
Growing MetaXplore sales
and clinical adoption in Australia
MetaXplore Test Sales Volume (AU)
16
MetaXplore All Time Ordering Clinicians (AU)
1488
6673
1036
Record Quarter with Strong Clinician Uptake
•
Q4 – 3,451 tests sold, up 88% vs PCP, a new
record kit sales quarter
•
Q4 – 790 ordering clinicians, up 89% vs PCP
•
Q4 annualised run-rate of 13,800 tests sold, up
88% vs PCP
•
Growth is underpinned by a continued increase
in the number of ordering clinicians
4392
721
2907
539
Q1
1782
955
H2FY23
185
H1FY24
H2FY24
H1FY25
H2FY25
H2FY23
H1FY24
H2FY24
H1FY25
H2FY25
Growing MetaXplore sales and clinical
adoption in the United Kingdom
MetaXplore Test Sales Volume (UK)
MetaXplore Ordering Clinicians (UK)
17
Breakout sales following full market access
800
219
675
700
600
500
400
300
Q1
200
26
100
22
0
H1FY25
H2FY25
H1FY25
H2FY25
•
Q4 test sales for 429, up 74% QoQ
•
Full market access was achieved at the
end of May
•
June delivered strong growth
underpinned by successful onboarding
and adoption by new ordering
clinicians
Growing MetaPanel sales and clinical
adoption in Australia
MetaPanel Test Sales Volume (AU)
MetaPanel Ordering Clinicians (AU)
467
127
402
112
155
39
0
H1FY24
H2FY24
H1FY25
H2FY25
H2FY24
H1FY25
H2FY25
18
Adoption continues to build gradually
•
Q4 sales of 266, up 85% vs PCP
•
Current focus is on development of
Gastroenterology specialists which will drive
adoption activity in the rest of the clinician
market. Expect a gradual rate of adoption over
the next year, with subsequent years providing
the opportunity for larger volume as KOL and
evidence development work starts to yield.
•
Supported by breakthrough study results
showing its clinical utility gastrointestinal
pathogen detection, combined with
engagement from multiple new specialist KOL
clinicians driving education and uptake in this
market development phase.
19
SUB-SECTION 3.2
BASE
Products where sales and revenue are expected to
remain largely consistent, with opportunity for future
growth incl. Supplements and International Partners.
Robust Supplement sales &
revenue in United Kingdom
Supplement Unit Sales (UK)
80,000
20
Supplement Revenue (UK)
$3,000,000
70,000
•
Total supplement sales $1.1m, down 11% vs
PCP reflecting transition due to greater focus
on Invivo branded and owned supplements
•
Invivo branded and owned supplements sales
$0.68m, up 12% vs PCP, with leading SKU
recording multiple record sales months
•
Strong growth for the hero PHGG prebiotic
supplement, driven by targeted digital
campaigns, Amazon storefront, and distributor
account management
$2,500,000
60,000
$2,000,000
50,000
40,000
$1,500,000
30,000
$1,000,000
Q1
20,000
$500,000
10,000
0
Growth focused on Invivo owned products
H2FY24
H1FY25
H2FY25
United Kingdom
$0
H2FY24
H1FY25
H2FY25
21
SUB-SECTION 3.3
LEGACY
Discontinued products & services being phased out.
Evolution of UK Test Sales
22
Strong progress in migration of customers and sales to MetaXplore
GI EcologiX Test Sales Units
MetaXplore Test Sales
900
500
50%
800
450
45%
400
40%
350
35%
300
30%
250
25%
200
20%
150
15%
100
10%
50
5%
700
MetaXplore Test Sales
600
500
400
300
200
100
-
Q1FY25
Q2FY25
Q3FY25
Q4FY25
0
Q2FY25
MetaXplore
Q3FY25
Q4FY25
% Total GI Tests
0%
Migration of customers and legacy
product discontinuation on track
•
June MetaXplore sales representing
54% of the total GI tests sales in the
UK
•
EcologiX test processing will close in
October-25.
•
Transition to MetaXplore expected
to complete by end of CY2025
23
SUB-SECTION 3.1
THERAPEUTICS
Attractive upside - leveraging Microba’s leading
databank with years of R&D and investment
Attractive Upside
24
A pipeline of assets backed by big-data, preclinical and
clinical validation, targeting deals
•
5+ years of investment to develop a rich
pipeline of live biotherapeutic assets
and data, leveraging Microba’s world
leading databank generated from it’s
testing business
•
Now moved to partnering to provide a
return on investment for shareholders
•
Microbiome therapeutics sector will see
upcoming sector deal catalysts, first
before end of CY2025
•
No further R&D expenditure from FY26
•
Recent deal precedents ranging
between $1.5 – $11B
Therapeutic Assets
Upcoming deal
Dealcatalysts
Catalysts
Upcoming
2x peer companies are expected to read out on key clinical trials by the end of 2025. The results from these trials if
positive would validate this new live-biotherapeutic modality, and deal precedents indicate that competitive deal
activity for these assets would follow. Microba’s leading data-driven platform and live-biotherapeutic assets, are best in
class and ready for this deal activity.
Microbiotica - Phase 1b First-in-Human trial, COMPOSER-1, for MB310 in ulcerative colitis (UC)
patients. Expected to read out before the end of CY25
Vedanta – Global, randomized, double-blind, placebo-controlled Phase 2 study COLLECTiVE202, for
VE202 in patients with mild-to-moderate UC. Study scheduled to complete late CY25
LBP = Live Biotherapeutic Product
25
SUB-SECTION 3.3
FOCUS & CATALYSTS
Key areas of focus & catalysts
Diagnostics
•
•
•
Financial Snapshot
Australia - continued momentum in core test sales
growth and clinical adoption
ASX Code
MAP
Market capitalisation1
$54m
United Kingdom - accelerating momentum in core
test sales growth and clinical adoption
Shares on issue
515.03m
Multiple upcoming MetaXplore feature releases
Cash Balance (30 June 2025)
Therapeutics
•
26
2 upcoming sector deal catalysts, expected in late
CY2025.
FY26 Guidance
52-week low / high1
$0.82 / $0.325
$11.7m
Major Shareholders
Shareholder
Ownership %2
Sonic Healthcare
19.14%
Perennial
14.99%
SA Microba Holdings
7.48%
•
Regional Break-even in Australia & United Kingdom
Thorney Investment Group
6.69%
•
>24,000 Core test volume
Macrogen
3.98%
Philip Hugenholtz
3.84%
Gene Tyson
3.82%
1 At 18 July 2025 | 2 At 31 December 2024
27
SECTION 4
Microba Overview
Whole Business Recap
28
SUB-SECTION 4.1
The Microbiome Opportunity
The next frontier in precision healthcare
29
Changing the gut microbiome can treat chronic disease.
21,000+
150+
Research publications
demonstrate a clear link
between chronic diseases and
the gut microbiome*
Gastrointestinal
Mental
Cardiovascular
PubMed search terms "gut microbiome" and "modulate" and "clinical study" and manually selecting for clinical trials with positive results indicated in the abstracts.
Global clinical studies
demonstrate that microbiome
modulation can influence disease
outcomes and clinical symptoms*
Cancer
Autoimmune
Allergy
Clear, global and ambitious vision
Broad-based
acceptance
Regular testing is
commonplace
The microbiome is
recognised by
healthcare professionals
and patients as critical
to health and disease
management.
High quality and
clinically useful
microbiome testing is
performed regularly –
initiated both by
patients and clinicians.
Usage of approved
therapeutics is
routine
Microbiome therapeutics
are approved and in
routine use for both
maintenance and
the treatment of multiple
chronic diseases.
30
Millions of patients
living healthier lives
Microbiome diagnostics
and therapeutics have
materially improved
millions of patient lives –
driving yet further
Share your feedback
Discover